Lot-to-lot consistency, immunogenicity, and safety of the Ad26.ZEBOV, MVA-BN-Filo Ebola virus vaccine regimen: A phase 3, randomized, double-blind, placebo-controlled trial

References

• Malvy D, McElroy AK, de Clerck H, Gunther S, van Griensven J. Ebola virus disease. Lancet. 2019;393:936–13. doi:10.1016/S0140-6736(18)33132-5.
   PubMed Web of Science ®Google Scholar
• Jacob ST, Crozier I, Fischer WA 2nd, Hewlett A, Kraft CS, Vega MA, Soka MJ, Wahl V, Griffiths A, Bollinger L, et al. Ebola virus disease. Nat Rev Dis Primers. 2020;6:13. doi:10.1038/s41572-020-0147-3.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. History of Ebola disease outbreaks. 30 Aug 2023. [ accessed 2023 Dec 12]. https://www.cdc.gov/vhf/ebola/history/chronology.html.
   Google Scholar
• Henao-Restrepo AM, Preziosi MP, Wood D, Moorthy V, Kieny MP. On a path to accelerate access to Ebola vaccines: the WHO’s research and development efforts during the 2014–2016 Ebola epidemic in West Africa. Curr Opin Virol. 2016;17:138–44. doi:10.1016/j.coviro.2016.03.008.
   PubMed Web of Science ®Google Scholar
• European Commission. Vaccine against Ebola: commission grants new market authorisations. Press release. European Commission: 2020 Jul 1 [accessed 7 Jul 2023]. https://ec.europa.eu/commission/presscorner/detail/en/IP_20_1248.
   Google Scholar
• European Medicines Agency. Zabdeno summary of product characteristics. [accessed 2023 Jul 7]. https://www.ema.europa.eu/en/documents/product-information/zabdeno-epar-product-information_en.pdf.
   Google Scholar
• European Medicines Agency. Mvabea summary of product characteristics. [accessed 2023 Jul 7]. https://www.ema.europa.eu/en/documents/product-information/mvabea-epar-product-information_en.pdf.
   Google Scholar
• World Health Organization. WHO prequalification of medical products (IVDs, medicines, vaccines and immunization devices, vector control): Zabdeno. [accessed 2024 Feb 12]. https://extranet.who.int/prequal/vaccines/p/zabdeno.
   Google Scholar
• World Health Organization. WHO prequalification of medical products (IVDs, medicines, vaccines and immunization devices, vector control): Mvabea. [accessed 2024 Feb 12]. https://extranet.who.int/prequal/vaccines/p/mvabea.
   Google Scholar
• World Health Oranization. Meeting of the strategic advisory group of experts on immunization, 22–24 March 2021: conclusions and recommendations. Wkly Epidemiol Rec. 2021;22:197–216.
   Google Scholar
• Milligan ID, Gibani MM, Sewell R, Clutterbuck EA, Campbell D, Plested E, Nuthall E, Voysey M, Silva-Reyes L, McElrath MJ, et al. Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia Ankara-vectored Ebola vaccines: a randomized clinical trial. JAMA. 2016;315:1610–23. doi:10.1001/jama.2016.4218.
   PubMed Web of Science ®Google Scholar
• Mutua G, Anzala O, Luhn K, Robinson C, Bockstal V, Anumendem D, Douoguih M. Safety and immunogenicity of a 2-dose heterologous vaccine regimen with Ad26.ZEBOV and MVA-BN-Filo Ebola vaccines: 12-month data from a phase 1 randomized clinical trial in Nairobi, Kenya. J Infect Dis. 2019;220:57–67. doi:10.1093/infdis/jiz071.
   PubMed Web of Science ®Google Scholar
• Barry H, Mutua G, Kibuuka H, Anywaine Z, Sirima SB, Meda N, Anzala O, Eholie S, Bétard C, Richert L, et al. Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: a randomised, placebo-controlled phase II clinical trial in Africa. PLoS Med. 2021;18:e1003813. doi:10.1371/journal.pmed.1003813.
   PubMed Web of Science ®Google Scholar
• Anywaine Z, Barry H, Anzal O, Mutua G, Sirima SB, Eholie S, Kibuuka H, Bétard C, Richert L, Lacabaratz C, et al. Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: a randomised, placebo-controlled, multicentre phase II clinical trial. PLoS Med. 2022;19:e1003865. doi:10.1371/journal.pmed.1003865.
   PubMed Web of Science ®Google Scholar
• Pollard AJ, Launay O, Lelievre JD, Lacabaratz C, Grande S, Goldstein N, Robinson C, Gaddah A, Bockstal V, Wiedemann A, et al. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2021;21:493–506. doi:10.1016/S1473-3099(20)30476-X.
   PubMed Web of Science ®Google Scholar
• Ishola D, Manno D, Afolabi MO, Keshinro B, Bockstal V, Rogers B, Owusu-Kyei K, Serry-Bangura A, Swaray I, Lowe B, et al. Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial. Lancet Infect Dis. 2022;22:97–109. doi:10.1016/S1473-3099(21)00125-0.
   PubMed Web of Science ®Google Scholar
• Afolabi MO, Ishola D, Manno D, Keshinro B, Bockstal V, Rogers B, Owusu-Kyei K, Serry-Bangura A, Swaray I, Lowe B, et al. Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial. Lancet Infect Dis. 2022;22:110–22. doi:10.1016/S1473-3099(21)00128-6.
   PubMed Web of Science ®Google Scholar
• PREVAC Study Team, Kieh M, Richert L, Beavogui AH, Grund B, Leigh B, D’Ortenzio E, Doumbia S, Lhomme E, Sow S, et al. Randomized trial of vaccines for Zaire Ebola virus disease. N Engl J Med. 2022;387:2411–24. doi:10.1056/NEJMoa2200072.
   PubMed Web of Science ®Google Scholar
• Manno D, Bangura A, Baiden F, Kamara AB, Ayieko P, Kallon J, Foster J, Conteh M, Connor NE, Koroma B, et al. Safety and immunogenicity of an Ad26.ZEBOV booster dose in children previously vaccinated with the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen: an open-label, non-randomised, phase 2 trial. Lancet Infect Dis. 2023;23:352–60. doi:10.1016/S1473-3099(22)00594-1.
   PubMed Web of Science ®Google Scholar
• Choi EML, Mustapher GAB, Omosa-Manyonyi G, Foster J, Anywaine Z, Musila Mutua M, Ayieko P, Vudriko T, Ann Mwangi I, Njie Y, et al. Safety and immunogenicity of an Ad26.ZEBOV booster vaccine in human immunodeficiency virus positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen against Ebola: a single-arm, open-label phase II clinical trial in Kenya and Uganda. Vaccine. 2023;41:7573–80. doi:10.1016/j.vaccine.2023.10.055.
   PubMed Web of Science ®Google Scholar
• Rudge TL Jr, Sankovich KA, Niemuth NA, Anderson MS, Badorrek CS, Skomrock ND, Cirimotich CM, Sabourin CL. Development, qualification, and validation of the Filovirus Animal Nonclinical Group anti-Ebola virus glycoprotein immunoglobulin G enzyme-linked immunosorbent assay for human serum samples. PloS One. 2019;14:e0215457. doi:10.1371/journal.pone.0215457.
   PubMed Web of Science ®Google Scholar
• Stieh DJ, Barouch DH, Comeaux C, Sarnecki M, Stephenson KE, Walsh SR, Sawant S, Heptinstall J, Tomaras GD, Kublin JG, et al. Safety and immunogenicity of Ad26-vectored HIV vaccine with mosaic immunogens and a novel mosaic envelope protein in HIV-uninfected adults: a phase 1/2a study. J Infect Dis. 2023;227:939–50. doi:10.1093/infdis/jiac445.
   PubMed Web of Science ®Google Scholar
• Bockstal V, Gaddah A, Goldstein N, Shukarev G, Bart S, Luhn K, Robinson C, Anumendem D, Leyssen M, Douoguih M. Assessments of different batches and dose levels of a heterologous two-dose Ad26.ZEBOV, MVA-BN-Filo vaccine regimen. NPJ Vaccines. 2021;6:157. doi:10.1038/s41541-021-00402-8.
   PubMed Web of Science ®Google Scholar
• McLean C, Dijkman K, Gaddah A, Keshinro B, Katwere M, Douoguih M, Robinson C, Solforosi L, Czapska-Casey D, Dekking L, et al. Persistence of immunological memory as a potential correlate of long-term, vaccine-induced protection against Ebola virus disease in humans. Front Immunol. 2023;14:1215302. doi:10.3389/fimmu.2023.1215302.
   PubMed Web of Science ®Google Scholar